Mounjaro vs. Wegovy: Which is More Effective for Weight Loss?

Last reviewed: July 8, 2026

Last updated: July 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Only one of these two medications is FDA approved for weight loss, and it is Wegovy. The Mounjaro prescribing information gives a single indication — an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. Mounjaro's active ingredient, tirzepatide, does hold a weight-management approval, but under a different brand: Zepbound, approved November 8, 2023. So the honest version of this comparison is Zepbound versus Wegovy — and that comparison has been run as a randomized trial, with tirzepatide producing the larger average weight reduction.

What Wegovy Is Approved to Do

Wegovy's labeling is unusually broad for a weight-management product. In combination with a reduced-calorie diet and increased physical activity, the injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and in patients aged 12 and older with obesity; to do the same in adults with overweight plus at least one weight-related comorbidity; and, under accelerated approval, to treat noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

That list is worth reading closely, because it is the substance of what "more effective" can mean. Wegovy is approved not only to reduce weight but to reduce a hard cardiovascular outcome and to treat a liver condition. Mounjaro is approved for none of those things, and neither is Zepbound.

The Randomized Head-to-Head: SURMOUNT-5

On the narrower question of how much weight comes off, there is a direct trial. SURMOUNT-5 was a phase 3b, open-label, controlled trial in 751 adults with obesity but without type 2 diabetes, randomized 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg), once weekly for 72 weeks.

Least-squares mean percent weight change at week 72 was −20.2% (95% CI −21.4 to −19.1) with tirzepatide and −13.7% (95% CI −14.9 to −12.6) with semaglutide, a statistically significant difference. Waist circumference fell 18.4 cm versus 13.0 cm. Participants on tirzepatide were more likely to reach weight reductions of at least 10%, 15%, 20% and 25%. Gastrointestinal events were the most common adverse events in both arms, mostly mild to moderate and concentrated during dose escalation.

Semaglutide's Answer Was a Higher Dose

The semaglutide arm in SURMOUNT-5 topped out at 2.4 mg, which was the highest approved weight-management dosage at the time. That is no longer the ceiling. In STEP UP, a phase 3b randomized trial in 1,407 adults with a BMI of 30 kg/m² or greater and without diabetes, mean body weight change at week 72 was −18.7% with semaglutide 7.2 mg versus −15.6% with semaglutide 2.4 mg, an estimated treatment difference of −3.1%.

The FDA approved the higher 7.2 mg dose, Wegovy HD, on March 19, 2026 for adult weight reduction. No trial has yet compared semaglutide 7.2 mg against tirzepatide head to head, so the SURMOUNT-5 result should be understood as a comparison against the 2.4 mg ceiling, not against everything semaglutide can now do.

The Outcomes Evidence Is Not Symmetrical

Weight reduction is an intermediate endpoint. Cardiovascular events are not. Wegovy's cardiovascular indication rests on a large outcomes trial described in its label, in which 8,803 patients were exposed to Wegovy for a median of 37.3 months and 8,801 to placebo for a median of 38.6 months, with a primary endpoint of time to first cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.

Tirzepatide does not currently carry a cardiovascular risk-reduction indication under either brand. What Zepbound does carry that Wegovy does not is an approval for moderate to severe obstructive sleep apnea in adults with obesity, granted in December 2024 on the basis of two 52-week randomized placebo-controlled studies in 469 adults. Which product is "more effective" therefore depends entirely on which outcome you are asking about.

Why the Mechanisms Differ

Semaglutide is a selective glucagon-like peptide-1 receptor agonist. Tirzepatide is described in its label as a GIP receptor and GLP-1 receptor agonist that binds and activates both, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner. Both GIP and GLP-1 are incretin hormones released from the gut after eating.

The dual mechanism is the most plausible explanation for the larger average effect, but "plausible explanation for a group difference" is a much weaker claim than "will work better for you." Response varied enormously within both arms of SURMOUNT-5, which is why the trial reported the proportion of participants hitting each threshold rather than a single expected result.

What Should Actually Drive the Choice

Approved indication comes first: if the goal is weight management, Mounjaro is not the labeled option, and the comparison is between Zepbound and Wegovy. After that, the relevant inputs are your other diagnoses — established cardiovascular disease, sleep apnea, liver fibrosis, diabetes — your tolerance of gastrointestinal effects, contraindications in the labels, and coverage, which usually tracks the indication rather than the ingredient.

None of those inputs is visible to a comparison article, and none of them is settled by a percentage. The prescriber who can see your full clinical picture makes that call, and the dosing schedule that applies to you is the one printed on your pharmacy label.

Compounded Preparations Sit Outside Both Labels

Compounded semaglutide and compounded tirzepatide are not FDA-approved finished products, and the FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. They are prepared by licensed pharmacies pursuant to prescriptions for individual patients. Wegovy, Ozempic, Zepbound and Mounjaro are the approved brands; a compounded preparation is not a generic version of any of them.

Every efficacy figure in this article was generated with an approved product at a studied dose. Keeping that attribution straight is the difference between citing evidence and borrowing it.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro approved for weight loss like Wegovy is?

No. Mounjaro's label gives one indication: improving glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Wegovy is approved for weight reduction and long-term maintenance, for cardiovascular risk reduction, and for noncirrhotic MASH. The tirzepatide product approved for chronic weight management is Zepbound, approved November 8, 2023, which is the correct comparator to Wegovy.

Which produced more weight loss in a head-to-head trial?

Tirzepatide. In SURMOUNT-5, 751 adults with obesity but without type 2 diabetes were randomized to the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks. Least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, with a larger waist circumference reduction as well. Both arms were dosed at weight-management levels, not diabetes levels.

Does the new higher-dose Wegovy change that comparison?

It has not been tested against tirzepatide. In the STEP UP trial of 1,407 adults with obesity, semaglutide 7.2 mg produced a mean weight change of −18.7% at week 72 versus −15.6% with semaglutide 2.4 mg, an estimated treatment difference of −3.1%. The FDA approved Wegovy 7.2 mg on March 19, 2026, but no randomized head-to-head against tirzepatide at that dose has been published.

Do these medications have different approved uses beyond weight?

Yes, and they do not overlap. Wegovy is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and for noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity. Neither product holds the other's additional indications.

How do I know which one is right for me?

That determination belongs to a licensed prescriber who can review your diagnoses, other medications, contraindications listed in each label, and tolerance of gastrointestinal effects. Trial results are group averages, and response varied widely within every arm of every trial cited here. Coverage also generally follows the approved indication rather than the ingredient, which affects what is actually accessible.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.